Cerubidine More Effective at Higher Doses for AML Treatment

A study conducted by the Eastern Oncology Cooperative Group and funded by the National Cancer Institute showed that initial chemotherapy with Cerubidine (daunorubicin) at higher doses increases survival time for acute myeloid leukemia (AML) patients. Although the results are only a preliminary analysis, they were revealed to allow the public to benefit from the positive results of the trial.

Ask your health care team if higher-dose daunorubicin chemotherapy is an option for you or your loved one. The purpose of studies like this are to improve treatment for everyone who leukemia, and it's important to make sure that this study's positive results benefit you or your loved one who has AML.